文献速递肾小球疾病慢性肾脏病血液净化与透析

经活检证实的儿童期起病狼疮性肾炎患儿及青少年的长期结局

Long-Term Outcomes of Children and Adolescents With Biopsy-Proven Childhood-Onset Lupus Nephritis.
PubMed 文献 · Kidney Int Rep · 2022-10-21

该回顾性队列纳入2001至2020年诊断的92例经活检证实的儿童期起病狼疮性肾炎患者,中位随访10.3年,无晚期慢性肾脏病、终末期肾病或死亡的生存率在1、5、10、15、20年分别为96.7%、94.2%、92.7%、83.2%和83.2%。多因素分析显示起病时需透析的严重肾衰竭、治疗12个月无反应及多次肾炎复发可预测晚期慢性肾脏病、终末期肾病或死亡。作者认为在有效免疫抑制、谨慎减药和保证用药依从性下长期结局似有改善,但不良结局发生率仍高。

要点

  • 儿童期起病狼疮性肾炎92例中90%为增殖性狼疮性肾炎(III/IV±V型)。
  • 6个月完全缓解65%、部分缓解20%;12个月完全缓解78%、部分缓解8%。
  • 起病时需透析的严重肾衰竭预测晚期慢性肾脏病、终末期肾病或死亡的校正风险比37.7。

核心结论

  • 作者认为在有效免疫抑制、谨慎减药和保证用药依从性下,儿童期起病狼疮性肾炎的长期结局似有改善,但不良结局发生率仍高。

研究设计与样本

  • 回顾性队列研究,纳入2001至2020年诊断的经活检证实的儿童期起病狼疮性肾炎患者,起病年龄小于18岁,共92例(女性78例,年龄13.7±3.3岁,均为中国人),随访10.3年(四分位距5.8-15.9)。

主要发现

  • 83例(90%)为增殖性狼疮性肾炎(III/IV±V型);36%以麦考酚酯诱导,34%以环磷酰胺诱导,55%以麦考酚酯维持免疫抑制。
  • 6个月完全缓解65%、部分缓解20%;12个月完全缓解78%、部分缓解8%。
  • 2例死亡(死亡率2.1/1000患者年),标准化死亡比22.3;3例(3.2%)发生终末期肾病,5例(5.4%)发生晚期慢性肾脏病。
  • 无晚期慢性肾脏病、终末期肾病或死亡的生存率在1年、5年、10年、15年、20年分别为96.7%、94.2%、92.7%、83.2%、83.2%。
  • 多因素分析显示起病时需透析的严重肾衰竭(校正风险比37.7,95%CI 4.0-355.6,P=0.002)、治疗12个月无反应(校正风险比11.2,95%CI 2.3-54.9,P=0.003)和多次肾炎复发(校正风险比2.6,95%CI 1.1-6.2,P=0.03)可预测晚期慢性肾脏病、终末期肾病或死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Long-term data pertaining to childhood-onset lupus nephritis (cLN) remain extremely scarce. METHODS: We conducted a retrospective cohort study of biopsy-proven cLN with onset age <18 years diagnosed from 2001 to 2020 to ascertain the long-term patient and kidney survival rates, and the incidence of advanced chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] <60 ml/min per 1.73 m2). RESULTS: A total of 92 subjects (78 female; age 13.7 ± 3.3 years; all Chinese) were included, with follow-up duration of 10.3 years (interquartile range, 5.8-15.9). Of these, 83 children (90%) had proliferative lupus nephritis (LN) (Class III/IV ± V). Mycophenolate was used for induction in 36%, whereas 34% received cyclophosphamide (CYC); 55% received mycophenolate as maintenance immunosuppression. The rates of complete remission (CR) and partial remission (PR) at 6 months and 12 months, respectively, were 65% and 20% and 78% and 8%. Two patients died (mortality rate 2.1/1000 patient-years), with a standardized mortality ratio of 22.3. Three patients (3.2%) developed end-stage kidney disease (ESKD), and advanced CKD occurred in 5 patients (5.4%). Survival rates without advanced CKD, ESKD, or death were 96.7%, 94.2%, 92.7%, 83.2% and 83.2% at 1 year, 5 years, 10 years, 15 years, and 20 years, respectively. Multivariate analysis revealed that severe kidney failure necessitating dialysis at presentation (adjusted hazard ratio 37.7, 95% confidence interval [CI] 4.0-355.6, P = 0.002), nonresponse (NR) after 12 months of treatment (adjusted hazard ratio 11.2, 95% CI 2.3-54.9, P = 0.003), and multiple nephritis flares (adjusted hazard ratio 2.6, 95% CI 1.1-6.2, P = 0.03) were predictive of advanced CKD, ESKD, or death. Other adverse outcomes included infections (2.9 episodes/100 patient-years), osteopenia (32%), hypertension (17%), short stature (14%), and avascular necrosis (7%). CONCLUSION: The long-term outcomes of cLN appeared to have improved in the present era with effective immunosuppression, cautious drug tapering, and assurance of medication adherence. There is still an unacceptably high prevalence of adverse outcomes.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chan EY, Yap DY, Wong WT, et al. Long-Term Outcomes of Children and Adolescents With Biopsy-Proven Childhood-Onset Lupus Nephritis. Kidney Int Rep. 2022. PMID: 36644360. doi:10.1016/j.ekir.2022.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。